Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Ventilation 66% Improvement Relative Risk Hospitalization 80% Ordinal scale 43% Time to improve one unit.. 30% no CI Recovery 25% Time to viral- 6% c19zinc.com Majeed et al. Zinc for COVID-19 RCT EARLY TREATMENT Favors zinc Favors control
Majeed, 92 patient zinc early treatment RCT: 43% improved recovery [p=0.004] and 6% faster viral clearance [p=0.47] https://c19p.org/majeedz
copied to clipboard
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients
Majeed et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545
11 Oct 2021    Source   PDF   Share   Tweet
RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment.
risk of mechanical ventilation, 66.2% lower, RR 0.34, p = 1.00, treatment 0 of 45 (0.0%), control 1 of 47 (2.1%), NNT 47, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 79.7% lower, RR 0.20, p = 0.49, treatment 0 of 45 (0.0%), control 2 of 47 (4.3%), NNT 24, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
relative ordinal scale, 43.0% better, RR 0.57, p = 0.004, treatment 45, control 47, day 28.
relative time to improve one unit on ordinal scale, 30.1% lower, relative time 0.70, treatment 45, control 47.
risk of no recovery, 24.6% lower, RR 0.75, p = 0.08, treatment 26 of 45 (57.8%), control 36 of 47 (76.6%), NNT 5.3, day 28.
time to viral-, 5.8% lower, relative time 0.94, p = 0.47, treatment 45, control 47.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Majeed et al., 11 Oct 2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 4 authors, this trial uses multiple treatments in the treatment arm (combined with curcumin, andrographolides, resveratrol, selenium, and piperine) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit